Browse

Preoperative [(18)F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer

DC Field Value Language
dc.contributor.authorChung, Hyun Hoon-
dc.contributor.authorNam, Byung-Ho-
dc.contributor.authorKim, Jae Weon-
dc.contributor.authorKang, Keon Wook-
dc.contributor.authorSong, Yong-Sang-
dc.contributor.authorKang, Soon-Beom-
dc.contributor.authorChung, June-Key-
dc.contributor.authorPark, Noh-Hyun-
dc.date.accessioned2012-07-03T08:30:42Z-
dc.date.available2012-07-03T08:30:42Z-
dc.date.issued2010-08-
dc.identifier.citationEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING; Vol.37 8; 1467-1473ko_KR
dc.identifier.issn1619-7070-
dc.identifier.urihttp://hdl.handle.net/10371/78312-
dc.description.abstractTo determine if preoperative [(18)F]FDG-PET/CT imaging has prognostic significance in patients with uterine cervical cancer. Patients with FIGO stage IB to IIA cervical cancer were imaged with integrated FDG PET/CT before radical surgery. The relationship between the maximum standardized uptake value (SUV(max)) of FDG in the primary tumour during PET/CT and recurrence was examined. Included in the study were 75 patients. Medical records including clinical data, treatment modalities, and treatment results were retrospectively reviewed. The median duration of follow-up was 13 months (range 3 to 58 months) after treatment. Median preoperative SUV(max) values in the primary tumours were significantly higher in patients with higher FIGO stages (p = 0.0149), pelvic lymph node metastasis (p = 0.0068), parametrial involvement (p = 0.0002), large (> 4 cm) tumour size (p = 0.0022), presence of lymphovascular space invasion (p = 0.0055), and deep cervical stromal invasion (p < 0.0001). In univariate analysis, lymph node metastasis, parametrial invasion, presence of lymphovascular space invasion, and preoperative SUV(max) (uncategorized values) in the primary tumour were significantly associated with recurrence. However, in multivariate analysis, preoperative SUV(max) (p = 0.014, HR 1.178, 95% CI 1.034-1.342), age (p = 0.021, HR 0.87, 95% CI 0.772-0.980), and parametrial involvement (p = 0.040, HR 27.974, 95% CI 1.156-677.043) by primary tumour were significantly associated with recurrence. Preoperative FDG uptake by the primary tumour showed a significant association with recurrence in patients with uterine cervical cancer.ko_KR
dc.language.isoenko_KR
dc.publisherSPRINGERko_KR
dc.subjectFDG PET/CTko_KR
dc.subjectSUVko_KR
dc.subjectRecurrenceko_KR
dc.subjectCervical cancerko_KR
dc.titlePreoperative [(18)F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancerko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor정현훈-
dc.contributor.AlternativeAuthor남병호-
dc.contributor.AlternativeAuthor김재원-
dc.contributor.AlternativeAuthor강건욱-
dc.contributor.AlternativeAuthor박노현-
dc.contributor.AlternativeAuthor송용상-
dc.contributor.AlternativeAuthor정준기-
dc.contributor.AlternativeAuthor강순범-
dc.identifier.doi10.1007/s00259-010-1413-5-
dc.citation.journaltitleEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING-
dc.description.citedreferenceLee YY, 2009, GYNECOL ONCOL, V115, P65, DOI 10.1016/j.ygyno.2009.06.022-
dc.description.citedreferenceKim YT, 2009, J GYNECOL ONCOL, V20, P1, DOI 10.3802/jgo.2009.20.1.1-
dc.description.citedreferenceHoang JK, 2008, J CLIN ONCOL, V26, P1459, DOI 10.1200/JCO.2007.14.3628-
dc.description.citedreferenceSchwarz JK, 2007, JAMA-J AM MED ASSOC, V298, P2289-
dc.description.citedreferenceHorn LC, 2007, GYNECOL ONCOL, V107, P310, DOI 10.1016/j.ygyno.2007.06.026-
dc.description.citedreferenceKidd EA, 2007, CANCER, V110, P1738, DOI 10.1002/cncr.22974-
dc.description.citedreferenceChung HH, 2007, GYNECOL ONCOL, V104, P529, DOI 10.1016/j.ygyno.2006.09.009-
dc.description.citedreferenceChung HH, 2006, GYNECOL ONCOL, V103, P165, DOI 10.1016/j.ygyno.2006.02.016-
dc.description.citedreferenceYen TC, 2006, INT J RADIAT ONCOL, V65, P1307-
dc.description.citedreferenceWUE F, 2006, GYNECOL ONCOL, V101, P147, DOI DOI 10.1016/J.YGYNO.2005.10.005-
dc.description.citedreferenceSasaki R, 2005, J CLIN ONCOL, V23, P1136, DOI 10.1200/JCO.2005.06.129-
dc.description.citedreferenceHigashi K, 2005, J NUCL MED, V46, P267-
dc.description.citedreferenceSchwarzbach MHM, 2005, ANN SURG, V241, P286, DOI 10.1097/01.sla.0000152663.61348.6f-
dc.description.citedreferenceDowney RJ, 2004, J CLIN ONCOL, V22, P3255, DOI 10.1200/JCO.2004.11.109-
dc.description.citedreferenceAllal AS, 2004, INT J RADIAT ONCOL, V59, P1295, DOI 10.1016/j.ijrobp.2003.12.039-
dc.description.citedreferenceGrigsby PW, 2004, J CLIN ONCOL, V22, P2167, DOI 10.1200/JCO.2004.09.035-
dc.description.citedreferenceEllenson LH, 2004, CANCER CELL, V5, P533-
dc.description.citedreferenceYen TC, 2004, J NUCL MED, V45, P22-
dc.description.citedreferenceWaggoner SE, 2003, LANCET, V361, P2217-
dc.description.citedreferenceAllal AS, 2002, J CLIN ONCOL, V20, P1398-
dc.description.citedreferenceHarris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704-
dc.description.citedreferenceGrigsby PW, 2001, J CLIN ONCOL, V19, P3745-
dc.description.citedreferenceBENEDET JL, 2001, J EPIDEMIOL BIOSTAT, V6, P7-
dc.description.citedreferenceVansteenkiste JF, 1999, J CLIN ONCOL, V17, P3201-
dc.description.citedreferenceRose PG, 1999, J CLIN ONCOL, V17, P41-
dc.description.citedreferenceLandoni F, 1997, LANCET, V350, P535-
dc.description.citedreferenceWERNERWASIK M, 1995, INT J RADIAT ONCOL, V32, P1309-
dc.description.citedreferenceDELGADO G, 1990, GYNECOL ONCOL, V38, P352-
dc.description.citedreferenceBOYCE J, 1981, GYNECOL ONCOL, V12, P154-
dc.description.citedreferenceCHUNG CK, 1980, AM J OBSTET GYNECOL, V138, P550-
dc.description.citedreferenceVANNAGELL JR, 1978, CANCER, V41, P228-
dc.description.tc5-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Nuclear Medicine (핵의학전공)Journal Papers (저널논문_핵의학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse